ObGyn and Women's Health Institute (Drs. Frisch, Llarena, Omosigho, Bradley, and Falcone); and Quantitative Health Sciences (Mr. Yao), Cleveland Clinic Foundation, Cleveland, Ohio; Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio (Mr. Mitchell, Ms. DeAngelo, and Ms. Arakelian); HRC Fertility, Pasadena, California (Dr. Llarena).
ObGyn and Women's Health Institute (Drs. Frisch, Llarena, Omosigho, Bradley, and Falcone); and Quantitative Health Sciences (Mr. Yao), Cleveland Clinic Foundation, Cleveland, Ohio; Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio (Mr. Mitchell, Ms. DeAngelo, and Ms. Arakelian); HRC Fertility, Pasadena, California (Dr. Llarena).
J Minim Invasive Gynecol. 2023 Aug;30(8):642-651. doi: 10.1016/j.jmig.2023.04.003. Epub 2023 Apr 10.
The objective of this study is to compare quality of life (QOL) for myomectomy with hysterectomy 1 to 5 years after surgical management for fibroids. This study evaluated the difference in QOL in a population of women of reproductive age, including those who desire fertility.
A retrospective cohort study.
Not applicable.
A large academic hospital.
A total of 142 women who underwent hysterectomy or myomectomy in 2015 to 2020. Included patients were women aged 18 years or older who underwent surgical intervention owing to uterine fibroids.
The 36-Item Short Form Health Survey (SF-36) provides a total score as a single measure of health-related QOL. The Uterine Fibroid Symptom Quality of Life Questionnaire for Hysterectomy and Myomectomy (UFS-QOL) is a patient-reported outcome measure of fibroid symptoms and health-related QOL after hysterectomy and myomectomy. There was no significant difference in SF-36 QOL scores in women after myomectomy who desired fertility compared with those who did not desire fertility, except in the social functioning domain (p = .025). UFS-QOL scores in women after myomectomy who desired fertility were not significantly different compared with women after myomectomy who did not desire fertility (p = .37). There were no significant differences between women who underwent myomectomy and hysterectomy in overall QOL scores on the SF-36 (p = .13) and UFS-QOL scores (p = .16).
Myomectomy is not associated with significant differences in measures of general health and QOL compared with hysterectomy, making it a viable fibroid management option for women who desire fertility. Our study highlights the importance of discussing fertility goals and QOL when counseling patients for surgical fibroid treatment.
本研究旨在比较子宫肌瘤患者接受子宫肌瘤剔除术与子宫切除术治疗后 1 至 5 年的生活质量(QOL)。本研究评估了生育期女性(包括希望生育的女性)人群中 QOL 的差异。
回顾性队列研究。
无。
一家大型学术医院。
共纳入 142 名 2015 年至 2020 年期间因子宫肌瘤接受子宫切除术或子宫肌瘤剔除术的女性。纳入标准为年龄 18 岁或以上、因子宫肌瘤接受手术干预的女性。
36 项简短健康调查问卷(SF-36)提供了一个总体评分,作为健康相关 QOL 的单一衡量标准。子宫肌瘤症状与子宫切除术和子宫肌瘤剔除术后健康相关 QOL 患者报告结局测量工具——子宫肌瘤症状质量生活调查问卷(UFS-QOL)。希望生育的子宫肌瘤剔除术后女性的 SF-36 QOL 评分与不希望生育的女性相比,除社会功能领域外(p=0.025),无显著差异。希望生育的子宫肌瘤剔除术后女性的 UFS-QOL 评分与不希望生育的女性相比,无显著差异(p=0.37)。SF-36 总体 QOL 评分(p=0.13)和 UFS-QOL 评分(p=0.16)方面,行子宫肌瘤剔除术与子宫切除术的女性之间无显著差异。
与子宫切除术相比,子宫肌瘤剔除术与一般健康和 QOL 测量指标的差异无统计学意义,因此对于希望生育的女性来说,是一种可行的子宫肌瘤治疗选择。我们的研究强调了在为手术治疗子宫肌瘤的患者提供咨询时讨论生育目标和 QOL 的重要性。